Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1966 2
1968 3
1970 3
1971 2
1972 1
1973 7
1975 2
1976 3
1977 12
1978 11
1979 5
1980 7
1981 8
1982 4
1983 10
1984 3
1985 10
1986 12
1987 12
1988 8
1989 12
1990 15
1991 10
1992 18
1993 26
1994 21
1995 18
1996 29
1997 25
1998 23
1999 33
2000 33
2001 27
2002 50
2003 57
2004 51
2005 39
2006 51
2007 49
2008 24
2009 30
2010 29
2011 21
2012 21
2013 19
2014 20
2015 33
2016 20
2017 22
2018 29
2019 26
2020 34
2021 44
2022 35
2023 27
2024 36
2025 16

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,121 results

Results by year

Filters applied: . Clear all
Page 1
VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan Clinical Oncology Group Study JCOG9801.
Tsukasaki K, Utsunomiya A, Fukuda H, Shibata T, Fukushima T, Takatsuka Y, Ikeda S, Masuda M, Nagoshi H, Ueda R, Tamura K, Sano M, Momita S, Yamaguchi K, Kawano F, Hanada S, Tobinai K, Shimoyama M, Hotta T, Tomonaga M; Japan Clinical Oncology Group Study JCOG9801. Tsukasaki K, et al. Among authors: ueda r. J Clin Oncol. 2007 Dec 1;25(34):5458-64. doi: 10.1200/JCO.2007.11.9958. Epub 2007 Oct 29. J Clin Oncol. 2007. PMID: 17968021 Clinical Trial.
Current status of immunotherapy.
Suzuki S, Ishida T, Yoshikawa K, Ueda R. Suzuki S, et al. Among authors: ueda r. Jpn J Clin Oncol. 2016 Mar;46(3):191-203. doi: 10.1093/jjco/hyv201. Epub 2016 Jan 26. Jpn J Clin Oncol. 2016. PMID: 26819277 Review.
BRAF V600E-induced distinct DNA damage response defines the therapeutic potential of p53 activation for TP53 wild-type colorectal cancer.
Tokuyama S, Kato H, Takahashi H, Ueda K, Arita A, Ueda R, Seto H, Sekido Y, Hata T, Hamabe A, Ogino T, Miyoshi N, Uemura M, Matsuoka K, Tsukamoto O, Yamamoto H, Doki Y, Eguchi H, Takashima S. Tokuyama S, et al. Among authors: ueda r. Carcinogenesis. 2024 Nov 22;45(11):857-867. doi: 10.1093/carcin/bgae040. Carcinogenesis. 2024. PMID: 38868979
The mechanisms of cancer immunoescape and development of overcoming strategies.
Yaguchi T, Sumimoto H, Kudo-Saito C, Tsukamoto N, Ueda R, Iwata-Kajihara T, Nishio H, Kawamura N, Kawakami Y. Yaguchi T, et al. Among authors: ueda r. Int J Hematol. 2011 Mar;93(3):294-300. doi: 10.1007/s12185-011-0799-6. Epub 2011 Mar 5. Int J Hematol. 2011. PMID: 21374075 Review.
Angioimmunoblastic T-cell lymphoma mice model.
Sato F, Ishida T, Ito A, Mori F, Masaki A, Takino H, Narita T, Ri M, Kusumoto S, Suzuki S, Komatsu H, Niimi A, Ueda R, Inagaki H, Iida S. Sato F, et al. Among authors: ueda r. Leuk Res. 2013 Jan;37(1):21-7. doi: 10.1016/j.leukres.2012.09.009. Epub 2012 Sep 29. Leuk Res. 2013. PMID: 23026775
CCR4 as a novel molecular target for immunotherapy of cancer.
Ishida T, Ueda R. Ishida T, et al. Among authors: ueda r. Cancer Sci. 2006 Nov;97(11):1139-46. doi: 10.1111/j.1349-7006.2006.00307.x. Epub 2006 Sep 5. Cancer Sci. 2006. PMID: 16952304 Free PMC article. Review.
1,121 results